News | January 30, 2025
Piramal Pharma Q3 FY25 revenue up 13%
CDMO business delivered high-teen revenue growth for 9MFY25 driven by continued traction in the on-patent commercial manufacturing and generic API business
CDMO business delivered high-teen revenue growth for 9MFY25 driven by continued traction in the on-patent commercial manufacturing and generic API business
OneSource operates five cGMP facilities and has a strong track record, with 138 successful regulatory and customer audits to date by all major regulatory bodies
PAT after MI is Rs. 41 crore which is 162% increase
Reported revenue from operations up by 11% to Rs. 944 crores Reported PAT (after exceptional items) up by 18% to Rs. 131 crore
The change is reflective of the company’s evolving vision aimed at further strengthening its global presence and a commitment to providing innovative solutions in the API and CDMO space
Investment will fund expansion to meet rising demand for CRDMO services
The certification marks a new chapter in Windlas Biotech’s growth trajectory,
Increases speed to market for drug developers working on nucleic acid therapeutics
The new brand name reflects the evolution from a generics-focused Contract Research Organization (CRO) to a drug development services enterprise
The facility is equipped with state-of-the-art technology to produce high-quality lyophilized (freeze-dried) products
Subscribe To Our Newsletter & Stay Updated
